Heart Failure
Conditions
Brief summary
Heart failure is currently not only a major medical but also a socio-economic problem. Its prevalence is estimated at 1-2% of the population with an exponential increase in older age groups. A very important part of the treatment of heart failure is the gradual uptitration of therapy to the maximum tolerated doses. Properly conducted therapy titration requires more frequent patient contact. Thanks to the introduction of telemedicine techniques, the investigators can communicate more effectively with the patient, reach the target doses of heart failure medication faster and subsequently reduce the number of hospitalizations due to worsening of heart failure. This study investigates effect of advanced telemonitoring of patients with heart failure in home environment.
Interventions
DEVICEMedimonitor
A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smartwatch, mobile ECG, blood pressure monitor, weight scales, pulse oximetry device.
Sponsors
University Hospital Olomouc
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* LVEF ≤ 40% * exclusion of obstructive coronary artery disease * NTproBNP ≥ 125pg/ml * ≥ 60 years of age * Informed written and verbal consent * Able to participate in study activities
Exclusion criteria
* LVEF ≥ 40% * Ischaemic ethiology of cardiomyopathy * NTproBNP ≤ 125pg/ml * Severe psychological disturbances * Absence of collaboration (informed consent) * BP ≤ 110mmHg without hypertensive medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the effect of step telemonitoring during uptitration of heart failure medication. | 3 month | Uptitration of therapy guided by data from the medical and other devices (tablet with smartwatch providing data from the pedometer, i.e. number of steps) provided to the patients with heart failure in home environment. |
| Evaluation of the effect of ECG telemonitoring during uptitration of heart failure medication. | 3 month | Uptitration of therapy guided by data from medical and other devices (tablet with mobile ECG) provided to the patients with heart failure in home environment. |
| Evaluation of the effect of blood pressure telemonitoring during uptitration of heart failure medication. | 3 month | Uptitration of therapy guided by data from medical and other devices (tablet and blood pressure monitor recording systolic and diastolic blood pressure) provided to the patients with heart failure in home environment. |
| Evaluation of the effect of body weight telemonitoring during uptitration of heart failure medication. | 3 month | Uptitration of therapy guided by data from medical and other devices (tablet and diagnostic weight scales for monitoring weight in kilograms) provided to the patients with heart failure in home environment. |
| Evaluation of the effect of body water telemonitoring during uptitration of heart failure medication. | 3 month | Uptitration of therapy guided by data from medical and other devices (tablet and diagnostic weight scales for monitoring body water percentage) provided to the patients with heart failure in home environment. |
| Evaluation of the effect of blood oxygen saturation telemonitoring during uptitration of heart failure medication. | 3 month | Uptitration of therapy guided by data from medical and other devices (tablet and pulse oximetry device to monitor blood oxygen saturation in percents) provided to the patients with heart failure in home environment. |
| Evaluation of changes of NTproBNP levels at the beginning vs. at the end of the study. | 3 month | Evaluation of changes of NTproBNPlevels as a marker of effective therapy of heart failure. |
| Evaluation of changes in LVEF echocardiographic parameter at the beginning vs. at the end of study. | 3 month | Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LVEF echocardiographic parameter |
| Evaluation of changes in LVEDD echocardiographic parameter at the beginning vs. at the end of study. | 3 month | Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LVEDD echocardiographic parameter |
| Evaluation of changes in LVESD echocardiographic parameter at the beginning vs. at the end of study. | 3 month | Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LVESD echocardiographic parameter |
| Evaluation of changes in LAVi echocardiographic parameter at the beginning vs. at the end of study. | 3 month | Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LAVi echocardiographic parameter |
| Evaluation of changes in diastolic dysfunction by echocardiography at the beginning vs. at the end of study. | 3 month | Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in diastolic dysfunction. |
Countries
Czechia
Outcome results
None listed